Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: Implications for a glioma phase 1 clinical trial

Human Gene Therapy Methods

Volumn 23, Issue 4, 2012, Pages 271-284

  Ghulam Muhammad, A K M ^a   Xiong, Weidong ^a,b   Puntel, Mariana ^a   Farrokhi, Catherine ^a   Kroeger, Kurt M ^a   Salem, Alireza ^a   Lacayo, Liliana ^a   Pechnick, Robert N ^a,c   Kelson, Kyle R ^a   Palmer, Donna ^d   Ng, Philip ^d   Liu, Chunyan ^a   Lowenstein, Pedro R ^a,b,c   Castro, Maria G ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DRUG ANTIBODY; ENZYME ANTIBODY; FMS LIKE TYROSINE KINASE LIGAND 3; GANCICLOVIR; IMMUNOSTIMULATING AGENT; NEUTRALIZING ANTIBODY; THYMIDINE KINASE; UNCLASSIFIED DRUG; UREA; VIRUS ANTIBODY; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CANCER GENE THERAPY; CHRONIC INFLAMMATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; GENE CONTROL; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; MALE; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; RAT; TOXICITY TESTING; UREA BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS PARTICLE; ADENOVIRUS; ANIMAL; ANIMAL BEHAVIOR; BLOOD ANALYSIS; BRAIN; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GLIOMA; HERPES SIMPLEX VIRUS 1; HUMAN; LEWIS RAT; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION;

ADENOVIRIDAE; ANIMALS; BEHAVIOR, ANIMAL; BLOOD CHEMICAL ANALYSIS; BRAIN; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE MODELS, ANIMAL; FMS-LIKE TYROSINE KINASE 3; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MALE; RATS; RATS, INBRED LEW; THYMIDINE KINASE; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

EID: 84872226609     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.060     Document Type: Article

References (63)

1. Ali, S., Curtin, J.F., Zirger, J.M., et al. (2004). Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther. 10, 1071-1084. (Pubitemid 39625251)
2. Ali, S., King, G.D., Curtin, J.F., et al. (2005). Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 65, 7194-7204. (Pubitemid 41161250)
3. Barcia, C., Gerdes, C., Xiong, W.D., et al. (2006). Immunological thresholds in neurological gene therapy: Highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol. 2, 309-322.
4. Barcia, C., Jimenez-Dalmaroni, M., Kroeger, K.M., et al. (2007). One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol. Ther. 15, 2154-2163. (Pubitemid 350148932)
5. Candolfi, M., Curtin, J.F., Xiong, W.D., et al. (2006). Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol. Ther. 14, 371-381. (Pubitemid 44207898)
6. Candolfi, M., Curtin, J.F., Nichols, W.S., et al. (2007). Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. J. Neurooncol. 85, 133-148. (Pubitemid 47629395)
7. Candolfi, M., Yagiz, K., Foulad, D., et al. (2009). Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity. Clin. Cancer Res. 15, 4401-4414.
8. Castro, M.G., Candolfi, M., Kroeger, K., et al. (2011). Gene therapy and targeted toxins for glioma. Curr. Gene Ther. 11, 155-180.
9. Charles, N.A., Holland, E.C., Gilbertson, R., et al. (2011). The brain tumor microenvironment. Glia 59, 1169-1180.
10. Chirmule, N., Propert, K., Magosin, S., et al. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583. (Pubitemid 29465516)
11. Cowsill, C., Southgate, T.D., Morrissey, G., et al. (2000). Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: Reduced cytotoxicity of a truncated HSV1-TK. Gene Ther. 7, 679-685. (Pubitemid 30255772)
12. Curtin, J.F., King, G.D., Barcia, C., et al. (2006). Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J. Immunol. 176, 3566-3577. (Pubitemid 43364004)
13. Curtin, J.F., Candolfi, M., Xiong, W., et al. (2008). Turning the gene tap off: Implications of regulating gene expression for cancer therapeutics. Mol. Cancer Ther. 7, 439-448. (Pubitemid 351482126)
14. Curtin, J.F., Liu, N., Candolfi, M., et al. (2009). HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6, e10.
15. Dewey, R.A., Morrissey, G., Cowsill, C.M., et al. (1999). Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat. Med. 5, 1256-1263. (Pubitemid 29535602)
16. Gerdes, C.A., Castro, M.G., and Lowenstein, P.R. (2000). Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol. Ther. 2, 330-338.
17. Ghulam Muhammad, A.K., Candolfi, M., King, G.D., et al. (2009). Antiglioma immunological memory in response to conditional cytotoxic/immune- stimulatory gene therapy: Humoral and cellular immunity lead to tumor regression. Clin. Cancer Res. 15, 6113-6127.
18. Gonzalez-Aparicio, M., Alzuguren, P., Mauleon, I., et al. (2011). Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 60, 341-349.
19. Grossman, S.A., Ye, X., Piantadosi, S., et al. (2010). Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16, 2443-2449.
20. Heimberger, A.B., and Sampson, J.H. (2011). Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma? Neuro. Oncol. 13, 3-13.
21. Hurtado-Lorenzo, A., David, A., Thomas, C., et al. (2003). Use of recombinant adenovirus for gene transfer into the rat brain: Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions. Methods Mol. Med. 76, 113-133.
22. Immonen, A., Vapalahti, M., Tyynela, K., et al. (2004). AdvHSVtk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10, 967-972. (Pubitemid 39419922)
23. Kiang, A., Hartman, Z.C., Liao, S., et al. (2006). Fully deleted adenovirus persistently expressing GAA accomplishes longterm skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice. Mol. Ther. 13, 127-134. (Pubitemid 41763490)
24. King, G.D., Kroeger, K.M., Bresee, C.J., et al. (2008a). Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol. Ther. 16, 682-690. (Pubitemid 351426169)
25. King, G.D., Muhammad, A.K., Curtin, J.F., et al. (2008b). Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro. Oncol. 10, 19-31. (Pubitemid 351250897)
26. King, G.D., Muhammad, A.K., Xiong, W., et al. (2008c). Highcapacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J. Virol. 82, 4680-4684. (Pubitemid 351563707)
27. King, G.D., Muhammad, A.K., Larocque, D., et al. (2011). Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol. Ther. 19, 1793-1801.
28. Lamartina, S., Cimino, M., Roscilli, G., et al. (2007). Helperdependent adenovirus for the gene therapy of proliferative retinopathies: Stable gene transfer, regulated gene expression and therapeutic efficacy. J. Gene Med. 9, 862-874. (Pubitemid 47543253)
29. Lorusso, G., and Ruegg, C. (2008). The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130, 1091-1103.
30. Lowenstein, P.R., and Castro, M.G. (2003). Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences. Gene Ther. 10, 946-954. (Pubitemid 36722429)
31. Lowenstein, P.R., and Castro, M.G. (2004). Recent advances in the pharmacology of neurological gene therapy. Curr. Opin. Pharmacol. 4, 91-97. (Pubitemid 38145844)
32. Markert, J.M., Liechty, P.G., Wang, W., et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and posttumor resection for recurrent GBM. Mol. Ther. 17, 199-207.
33. McCormack, W.M., Jr., Seiler, M.P., Bertin, T.K., et al. (2006). Helper-dependent adenoviral gene therapy mediates longterm correction of the clotting defect in the canine hemophilia A model. J. Thromb. Haemost. 4, 1218-1225.
34. Mineharu, Y., King, G.D., Muhammad, A.K., et al. (2011). Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin. Cancer Res. 17, 4705-4718.
35. Morral, N., O'Neal, W., Rice, K., et al. (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U.S.A. 96, 12816-12821. (Pubitemid 29513585)
36. Muhammad, A.K., Puntel, M., Candolfi, M., et al. (2010). Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin. Pharmacol. Ther. 88, 204-213.
37. Ng, P., Beauchamp, C., Evelegh, C., et al. (2001). Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol. Ther. 3, 809-815. (Pubitemid 32519562)
38. Nwanegbo, E., Vardas, E., Gao, W., et al. (2004). Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11, 351-357. (Pubitemid 38380817)
39. Oka, K., Belalcazar, L.M., Dieker, C., et al. (2007). Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. Gene Ther. 14, 191-202. (Pubitemid 46152622)
40. Palmer, D., and Ng, P. (2003). Improved system for helper-dependent adenoviral vector production. Mol. Ther. 8, 846-852. (Pubitemid 37527461)
41. Palmer, D.J., and Ng, P. (2004). Physical and infectious titers of helper-dependent adenoviral vectors: A method of direct comparison to the adenovirus reference material. Mol. Ther. 10, 792-798. (Pubitemid 39272868)
42. Palmer, D.J., and Ng, P. (2005). Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. 16, 1-16. (Pubitemid 40250327)
43. Palmer, D.J., and Ng, P. (2011). Rescue, amplification, and largescale production of helper-dependent adenoviral vectors. Cold Spring Harb. Protoc. 2011, 857-866
44. Parks, R.J., Chen, L., Anton, M., et al. (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cremediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570. (Pubitemid 26424159)
45. Pietras, K., and Ostman, A. (2010). Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res. 316, 1324-1331.
46. Puntel, M., Curtin, J.F., Zirger, J.M., et al. (2006). Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum. Gene Ther. 17, 531-544. (Pubitemid 43794492)
47. Puntel, M., Kroeger, K.M., Sanderson, N.S., et al. (2010a). Gene transfer into rat brain using adenoviral vectors. Curr. Protoc. Neurosci. Chapter 4, Unit 4.24.
48. Puntel, M., Muhammad, A.K., Candolfi, M., et al. (2010b). A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and Tet-inducible expression of Flt3L for glioma therapeutics. J. Virol. 84, 6007-6017.
49. Schiedner, G., Morral, N., Parks, R.J., et al. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18, 180-183. (Pubitemid 28082470)
50. Schillinger, K.J., Tsai, S.Y., Taffet, G.E., et al. (2005). Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc. Natl. Acad. Sci. U.S.A. 102, 13789-13794. (Pubitemid 41377657)
51. Stupp, R., Mason, W.P., Van Den Bent, M.J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996. (Pubitemid 40349501)
52. Sul, J., and Fine, H.A. (2010). Malignant gliomas: New translational therapies. Mt. Sinai J. Med. 77, 655-666.
53. Sumida, S.M., Truitt, D.M., Lemckert, A.A., et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174, 7179-7185. (Pubitemid 40705685)
54. Sun, C., Zhang, Y., Feng, L., et al. (2011). Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 29, 3837-3841.
55. Szabo, A.T., and Carpentier, A.F. (2011). Immunotherapy in human glioblastoma. Rev. Neurol. (Paris) 167, 668-672.
56. Terashima, T., Oka, K., Kritz, A.B., et al. (2009). DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Invest. 119, 2100-2112.
57. Thomas, C.E., Schiedner, G., Kochanek, S., et al. (2000). Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U.S.A. 97, 7482-7487. (Pubitemid 30431489)
58. Thomas, C.E., Birkett, D., Anozie, I., et al. (2001a). Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlatewith decreased vector-mediated transgene expression in the brain. Mol. Ther. 3, 36-46. (Pubitemid 32509803)
59. Thomas, C.E., Schiedner, G., Kochanek, S., et al. (2001b). Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel highcapacity adenovirus vectors. Hum. Gene Ther. 12, 839-846. (Pubitemid 32692349)
60. Toietta, G., Mane, V.P., Norona, W.S., et al. (2005). Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. U.S.A. 102, 3930-3935. (Pubitemid 40388534)
61. Vauleon, E., Avril, T., Collet, B., et al. (2010). Overview of cellular immunotherapy for patients with glioblastoma. Clin. Dev. Immunol. 2010, 689171.
62. Weller, M. (2011). Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med. Wkly. 141, w13210.
63. Xiong, W., Goverdhana, S., Sciascia, S.A., et al. (2006). Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol. 80, 27-37.